NCT04543890 - A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

June 1, 2023

Study Completion Date

June 1, 2025

Conditions

Small Cell Lung Cancer Limited Stage

Interventions

RADIATION

Hyperfractionated radiotherapy

Thoracic radiotherapy (45 Gy/30 fractions) for the Hyperfractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).

RADIATION

Hypofractionated radiotherapy

Thoracic radiotherapy (45 Gy/15 fractions) for the Hypofractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).

DRUG

Etoposide

Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.

DRUG

Cisplatin

Cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.

Trial Locations (1)

RECRUITING

Zhejiang Cancer Hospital, Hangzhou